Wellington Management Group LLP Freeline Therapeutics Holdings PLC Transaction History

Wellington Management Group LLP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$0.92 - $2.03 $404,611 - $892,783	-439,795 Closed	0 $0
Q4 2021 Feb 11, 2022	SELL	$1.97 - $3.45 $443,330 - $776,391	-225,041 Reduced 33.85%	439,795 $866,000
Q3 2021 Nov 15, 2021	SELL	$3.04 - $8.9 $4.06 Million - $11.9 Million	-1,337,115 Reduced 66.79%	664,836 $2.29 Million
Q2 2021 Aug 16, 2021	SELL	$8.15 - $13.9 $1.75 Million - $2.99 Million	-215,142 Reduced 9.7%	2,001,951 $16.3 Million
Q1 2021 May 17, 2021	SELL	$12.3 - $18.2 $1.66 Million - $2.45 Million	-134,680 Reduced 5.73%	2,217,093 $27.3 Million
Q4 2020 Feb 12, 2021	BUY	$14.94 - $18.3 $5.21 Million - $6.38 Million	348,741 Added 17.41%	2,351,773 $42.9 Million
Q3 2020 Nov 16, 2020	BUY	$15.45 - $18.12 $30.9 Million - $36.3 Million	2,003,032 New	2,003,032 $31.3 Million

30.1K

Ticker FRLN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 64,972,300
Description
Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its advanced product candidate is verbrinacogene setparvovec (FLT180a), a gene therapy product candidate that is in P...

Get notified when there are updates to the investment portfolio of Wellington Management Group LLP, based on Form 13F filings with the SEC.

Stay updated on Wellington Management Group LLP with notifications on news.